Searching for treatments for non-G12C-KRAS mutant cancers.
Loading...
Embargo End Date
ICR Authors
Authors
Guo, C
Banerji, U
Banerji, U
Document Type
Journal Article
Date
2021-08-31
Date Accepted
2021-03-11
Abstract
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRASG12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF-MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.
Citation
British journal of cancer, 2021
Source Title
Publisher
SPRINGERNATURE
ISSN
0007-0920
eISSN
1532-1827
Collections
Research Team
Clinical Pharmacology – Adaptive Therapy
Clinical Pharmacology – Adaptive Therapy
Clinical Pharmacology – Adaptive Therapy